Røge BT - Search Results

1

Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.

Sølund C, Andersen ES, Mössner B, Laursen AL, Røge BT, Kjær MS, Gerstoft J, Christensen PB, Pedersen MS, Schønning K, Fahnøe U, Bukh J, Weis N. Sølund C, et al. Among authors: roge bt. Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1177-1186. doi: 10.1097/MEG.0000000000001192. Eur J Gastroenterol Hepatol. 2018. PMID: 29994874 Clinical Trial.

2

Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir.

Røge BT, Katzenstein TL, Gerstoft J. Røge BT, et al. Scand J Infect Dis. 2001;33(4):306-11. doi: 10.1080/003655401300077388. Scand J Infect Dis. 2001. PMID: 11345223 Clinical Trial.

3

Skeletal muscle mitochondrial function and exercise capacity in HIV-infected patients with lipodystrophy and elevated p-lactate levels.

Røge BT, Calbet JA, Møller K, Ullum H, Hendel HW, Gerstoft J, Pedersen BK. Røge BT, et al. AIDS. 2002 May 3;16(7):973-82. doi: 10.1097/00002030-200205030-00003. AIDS. 2002. PMID: 11953463

4

Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.

Røge BT, Katzenstein TL, Nielsen HL, Gerstoft J. Røge BT, et al. HIV Med. 2003 Jan;4(1):38-47. doi: 10.1046/j.1468-1293.2003.00133.x. HIV Med. 2003. PMID: 12534958 Free article.

5

Virological and immunological profiles among patients with undetectable viral load followed prospectively for 24 months.

Katzenstein TL, Ullum H, Røge BT, Wandall J, Dickmeiss E, Barrington T, Skinhøj P, Gerstoft J. Katzenstein TL, et al. Among authors: roge bt. HIV Med. 2003 Jan;4(1):53-61. doi: 10.1046/j.1468-1293.2003.00119.x. HIV Med. 2003. PMID: 12534960 Free article.

6

Natural history of hyperlactataemia in human immunodeficiency virus-1-infected patients during highly active antiretroviral therapy.

Huynh TK, Lüttichau HR, Roge BT, Gerstoft J. Huynh TK, et al. Among authors: roge bt. Scand J Infect Dis. 2003;35(1):62-6. doi: 10.1080/0036554021000026992. Scand J Infect Dis. 2003. PMID: 12685887

7

K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

Røge BT, Katzenstein TL, Obel N, Nielsen H, Kirk O, Pedersen C, Mathiesen L, Lundgren J, Gerstoft J. Røge BT, et al. Antivir Ther. 2003 Apr;8(2):173-82. Antivir Ther. 2003. PMID: 12741630 Clinical Trial.

8

Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations.

Mathiesen S, Roge BT, Weis N, Lundgren JD, Obel N, Gerstoft J. Mathiesen S, et al. Among authors: roge bt. AIDS. 2004 Apr 30;18(7):1076-8. doi: 10.1097/00002030-200404300-00020. AIDS. 2004. PMID: 15096815 No abstract available.

9

Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.

Røge BT, Barfod TS, Kirk O, Katzenstein TL, Obel N, Nielsen H, Pedersen C, Mathiesen LR, Lundgren JD, Gerstoft J. Røge BT, et al. HIV Med. 2004 Sep;5(5):344-51. doi: 10.1111/j.1468-1293.2004.00233.x. HIV Med. 2004. PMID: 15369509 Free article. Clinical Trial.

10

Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.

Mathiesen S, Dam E, Roge B, Joergensen LB, Laursen AL, Gerstoft J, Clavel F. Mathiesen S, et al. Antivir Ther. 2007;12(3):335-43. Antivir Ther. 2007. PMID: 17591023

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters